NFE2L2 and hepatocellular carcinoma: Apatinib combined with PD-1 inhibitor had an inhibitory effect on Nrf2 and p62, and the inhibition was more pronounced after the combined administration of CPT, suggesting that CPT could enhance HCC sensitivity to apatinib.